Lonza acquires Simbiosys Biowares' preclinical cell and molecular biology group

Saturday, 21 November, 2009 | Supplied by: Lonza Australia Pty Ltd



Lonza has completed the acquisition of the preclinical cell and molecular biology assets of Simbiosys Biowares India, a biology outsourcing company, expanding its cell-biology platform.

Simbiosys’s cell and molecular biology group specialises in primary cell isolation and tissue sourcing and in performing preclinical services to mid-size pharmaceutical companies.

Simbiosys Biowares India offers preclinical services in the areas of: drug discovery services (includes lead validation and lead development using in-vitro and in-vivo ADME-Tox assays); molecular biology contract research services (including DNA amplification and cloning, DNA/RNA isolation, synthetic gene construction and quantitative PCR); biopharmaceutical services (includes process design optimisation of fermentation technology for producing small-molecules, proteins and mAbs for therapeutic, diagnostic and research applications).

Online: www.lonza.com
Phone: 03 9550 0883
Related Products

BioGX Xfree COVID-19 Direct RT-PCR test

The Xfree COVID-19 Direct RT-PCR test is a complete test in a single vial, lyophilised...

Bio-Rad Laboratories CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems

Bio-Rad Laboratories' CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems are suitable for...

PCR Biosystems NGSBIO Library Quant Kit for Illumina

The kit contains all the components necessary for sensitive quantification of DNA libraries prior...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd